/

VSTM

Verastem, Inc.Closed

7.45−0.80 −9.70%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 7.53 +1.04%

Open

8.20

Prev close

8.25

Day range

7.458.20

52-week range

3.4310.82

Volume

3.39M1.50×

Mkt cap

674.70M

P/E ttm

—

Fwd P/E

-9.93

EPS ttm

-2.45

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−31.15%

Price Chart

Yahoo Finance · delayed

VSTMOct 13, 2026O 8.15H 8.20L 7.45C 7.45−0.80 (−9.70%)Vol 3.42M

SMA 507.45
SMA 2006.04

1Y change −19.81% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VSTM Verastem, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.87%
1 month: +1.78%
3 months: +33.75%
6 months: +21.34%
Year to date: −3.50%
1 year: −19.81%

Valuation & ownership

Market cap: 674.70M
Enterprise value: 622.67M
P/E (ttm): —
Forward P/E: -9.93
PEG ratio: —
Price / book: 13.50
Price / sales (ttm): 7.71
EV / EBITDA: -3.92
EPS (ttm): -2.45
EPS (forward): -0.7500
Beta (5y monthly): 0.39
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 90.56M
Float: 70.50M
Short % of float: 16.62%
Short ratio (days): 6.19
Held by insiders: 1.09%
Held by institutions: 110.43%
Avg volume (3m): 2.26M
50-day average: 7.42
200-day average: 6.04
52-week change: −19.81%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 45.3
vs 50-day SMA: −0.05%
vs 200-day SMA: +23.33%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.99%
Realised vol (20d, ann.): 64.9%
From 52-week high: −31.15%
From 52-week low: +117.20%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.10 on a 1 (strong buy) – 5 (sell) scale

Mean target

15.00

+101.34% implied

Low 11.00Median 14.00High 19.00

Recommendation trend

Now10 / 0 / 0
1m ago10 / 0 / 0

DES

About Verastem, Inc.

Yahoo Finance profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 102

SEAS

Seasonality · VSTM

2012–2026 · monthly returns

Strongest month Nov +13.19%Weakest month Oct −10.19%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-21.0	-6.2	-7.3	3.0	-20.7	-11.8	51.8	24.5	11.5	-7.5			−3.5%
2025	17.6	-7.9	7.7	24.2	0.4	-44.8	48.7	49.9	-4.5	7.0	12.6	-27.4	+49.3%
2024	44.3	6.0	-5.3	-15.4	-60.3	-24.7	-12.8	-3.8	19.6	25.8	42.0	-3.2	−36.5%
2023	62.5	-20.0	-19.2	-7.1	161.5	-39.2	48.7	-11.8	-16.7	-22.8	9.7	18.1	+69.6%
2022	-25.4	-21.6	17.5	0.7	-9.9	-9.4	-7.8	8.4	-26.7	-50.6	9.5	-13.0	−80.5%
2021	-8.5	20.5	5.1	24.3	26.1	5.2	-20.6	-18.0	16.2	-15.6	2.7	-23.2	−3.8%
2020	40.3	48.4	-5.4	-28.4	-1.6	-7.5	-22.1	-6.0	-4.0	-0.8	67.5	6.0	+59.0%
2019	-2.4	-8.2	-1.7	-28.0	-38.0	14.4	-0.7	-16.0	-4.0	-9.9	25.7	-2.2	−60.1%
2018	15.6	-13.8	-2.6	39.9	34.1	23.1	11.9	29.4	-27.2	-30.1	0.6	-34.1	+9.4%
2017	13.4	-10.2	81.6	-6.3	6.2	5.8	66.5	7.4	20.5	-18.7	10.2	-27.1	+174.1%
2016	-35.5	-6.7	41.1	4.4	-9.7	-12.8	7.7	-3.6	-1.5	-6.0	-8.8	-1.8	−39.8%
2015	-20.1	1.9	36.7	-18.4	4.2	-12.8	-3.2	-16.6	-70.6	2.8	23.4	-18.1	−79.6%
2014	10.2	6.4	-19.3	-22.6	11.1	-2.4	-18.4	17.9	-2.2	11.4	-2.0	-1.7	−19.8%
2013	13.3	-5.4	2.1	2.1	-2.6	45.2	9.4	-9.5	-9.5	-19.7	5.8	7.8	+29.7%
2012		5.8	-5.8	-5.0	-3.3	-3.5	-3.6	-7.7	8.9	-15.4	-14.2	29.1	−19.8%

INSD

Insider Activity · VSTM

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

360K shares

Sells, 6 months

27.1K shares

Net shares

+332.9K

Net change in insider shares

+50.80%

Date	Insider	Transaction	Shares	Value
Sep 20, 2026	Calkins DanielChief Financial Officer	Sale at price 7.70 per share.	55	$424
Aug 2, 2026	Paterson Daniel WChief Executive Officer	Sale at price 5.81 per share.	1.3K	$7.57K
Jun 21, 2026	Paterson Daniel WChief Executive Officer	Sale at price 4.18 per share.	20.9K	$87.24K
Jun 21, 2026	Calkins DanielChief Financial Officer	Sale at price 4.13 - 4.18 per share.	4.1K	$17.09K
May 20, 2026	Stuglik Brian MDirector	Stock Award(Grant) at price 0.00 per share.	36K	—
May 20, 2026	Kapur AnilDirector	Stock Award(Grant) at price 0.00 per share.	36K	—
May 20, 2026	Robertson MichelleDirector	Stock Award(Grant) at price 0.00 per share.	36K	—
May 20, 2026	Bunn Paul ADirector	Stock Award(Grant) at price 0.00 per share.	36K	—
May 20, 2026	Tollefson Karin AnnaDirector	Stock Award(Grant) at price 0.00 per share.	36K	—
May 20, 2026	Johnson John H.Director	Stock Award(Grant) at price 0.00 per share.	36K	—
May 20, 2026	Bailey Michael PDirector	Stock Award(Grant) at price 0.00 per share.	108K	—
May 20, 2026	Rowinsky Eric K.Director	Stock Award(Grant) at price 0.00 per share.	36K	—
May 3, 2026	Paterson Daniel WChief Executive Officer	Sale at price 5.82 per share.	806	$4.69K
Mar 19, 2026	Calkins DanielChief Financial Officer	Stock Award(Grant) at price 5.74 per share.	57	$327
Feb 3, 2026	Paterson Daniel WChief Executive Officer	Sale at price 6.69 per share.	970	$6.49K
Jan 20, 2026	Paterson Daniel WChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	213.8K	—
Jan 20, 2026	Calkins DanielChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	16.7K	—
Jan 11, 2026	Paterson Daniel WChief Executive Officer	Sale at price 7.16 per share.	10.3K	$73.90K
Jan 11, 2026	Calkins DanielChief Financial Officer	Sale at price 7.16 per share.	5K	$36.08K
Dec 23, 2025	Calkins DanielChief Financial Officer	Sale at price 7.86 per share.	80	$629

VSTM

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VSTM

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Verastem, Inc.

Seasonality · VSTM

Insider Activity · VSTM

Congress Trades · VSTM

Investors Holding VSTM

Investors Holding VSTM

Congress Trades · VSTM

Insider Activity · VSTM

Seasonality · VSTM

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Verastem, Inc.

Financial Snapshot

Earnings & Dividends

News